Elevations in C-reactive protein (CRP) are associated with increased cardiovascular disease (CVD) risk, increased HIV disease progression, and death in HIV-infected patients. Use of abacavir has been reported to increase CVD risk. We assessed the effect of virologically suppressive efavirenz (EFV)-based antiretroviral therapy on high sensitivity CRP (hsCRP) levels over a 96-week period with particular attention to the effect of gender and abacavir use. Banked sera from entry and week 96 visits of AIDS Clinical Trials Group A5095 participants were assayed for hsCRP, then analyzed by gender, abacavir randomization, and for correlation with changes in fasting metabolic parameters. Analyses of hsCRP were conducted in two phases and involved a total of 145 men and 51 women. hsCRP did not differ by gender at baseline but higher levels were seen at week 96 in women (median 6 mg/liter; Q1, Q3, 1.8, 13.8) compared to men (median 1.6 mg/liter; Q1, Q3, 0.9, 4.2, p < 0.001), with an estimated shift in hsCRP by gender of 2.5 mg/liter (95% CI 1.0, 5.1). There was no difference in hsCRP levels by abacavir use. Changes in hsCRP did not correlate with changes in insulin resistance or with changes in fasting lipids. Durably virologically suppressive therapy with EFV-based regimens did not decrease hsCRP levels over a 96-week period. hsCRP levels increased significantly only in women. Randomization to abacavir had no effect on changes in hsCRP levels. Changes in hsCRP levels did not correlate with changes in fasting metabolic parameters.
Get full access to this article
View all access options for this article.
References
1.
DaneshJ, WhincupP, WalkerMet al.Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ, 2000; 321,7255:199–204.
2.
LauB, SharrettAR, KingsleyLAet al.C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med, 2006; 166,1:64–70.
3.
FeldmanJG, GoldwasserP, HolmanS, DeHovitzJ, MinkoffH. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr, 2003; 32,2:210–214.
4.
HenryK, KitchD, DubeMet al.C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS, 2004; 18,18:2434–2437.
5.
SabinCA, WormSW, WeberRet al.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet, 2008; 371,9622:1417–1426.
6.
WormSW, SabinC, WeberRet al.Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis Feb1, 2010; 201,3:318–330.
7.
DAD Study Groups: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS, 2008; 22,14:F17–24.
8.
CooperD, BlochM, HumphriesA, AminJ, BakerD, EmeryS, CarrA. for the STEAL Study Investigators: Simplification with Fixed-dose Tenofovir/Emtricitabine or Abacavir/Lamivudine in Adults with Suppressed HIV Replication: The STEAL Study, a Randomized, Open-label, 96-Week, Non-inferiority Trial. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009. Abstract 576.
9.
BrothersCH, HernandezJE, CutrellAGet al.Risk of myocardial infarction and abacavir therapy: No increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr, 2009; 51,1:20–28.
10.
LangS, Mary-KrauseM, CotteLet al.Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort C04. Arch Infern Med Jul 26, 2010; 170,14:1228–1238.
11.
LichtensteinK, BucknerK, ArmonC, TedaldiE, ChmielJ, WoodKet al.Low CD4 Count is an Important Risk Factor for Cardiovascular Disease in the US HIV Outpatient Study (HOPS)17th IAC 2008: Poster THPE0236,2008.
12.
GulickRM, RibaudoHJ, ShikumaCMet al.Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med, 2004; 350,18:1850–1861.
13.
ShikumaCM, YangY, GlesbyMJ, MeyerWA, TashimaKT, RibaudoHJ, WebbN, BastowB, KuritzkesDR, GulickRM. for the AIDS Clinical Trials Group Protocol A5095 Study Team: Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study—A5095)J Acquir Immune Defic Syndr, 2007; 44,5:540–550.
14.
PearsonTA, MensahGA, AlexanderRWet al.Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 2003; 107,3:499–511.
15.
IkonomidisI, StamatelopoulosK, LekakisJ, VamvakouGD, KremastinosDT. Inflammatory and non-invasive vascular markers: The multimarker approach for risk stratification in coronary artery disease. Atherosclerosis, 2008; 199,1:3–11.
16.
DaneshJ, WheelerJG, HirschfieldGMet al.C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med, 2004; 350,14:1387–1397.
17.
RidkerPM, CannonCP, MorrowDet al.C-reactive protein levels and outcomes after statin therapy. N Engl J Med., 2005; 352,1:20–28.
18.
RidkerPM, CookN. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation, 2004; 109,16:1955–1959.
19.
RidkerPM, BuringJE, CookNR, RifaiN. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation, 2003; 107,3:391–397.
20.
ReingoldJ, WankeC, KotlerDet al.Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: The fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr, 2008; 48,2:142–148.
21.
TriantVA, MeigsJB, GrinspoonSK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr, 2009; 51,3:268–273.
22.
DrainPK, KupkaR, MsamangaGI, UrassaW, MugusiF, FawziWW. C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS, 2007; 21,15:2067–2075.
23.
McComsey GA SmithKY, PatelP, BellosNC, SloanL, LackeyP, KumarPN, Sutherland-PhillipsDH, YauL, ShaeferMS. Similar Reductions in Markers of Inflammation and Endothelial Activation after Initiation of Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC) in the HEAT Study. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009.
24.
CalabroP, ChangDW, WillersonJT, YehET. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: Linking obesity to vascular inflammation. J Am Coll Cardiol, 2005; 46,6:1112–1113.
25.
CalabroP, WillersonJT, YehET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation, 2003; 108,16:1930–1932.
26.
KushnerI, RzewnickiD, SamolsD. What does minor elevation of C-reactive protein signify?Am J Med, 2006; 119,2:166e17–28.
27.
SaltevoJ, VanhalaM, KautiainenH, KumpusaloE, LaaksoM. Gender differences in C-reactive protein, interleukin-1 receptor antagonist and adiponectin levels in the metabolic syndrome: A population-based study. Diabet Med, 2008; 25,6:747–750.
28.
BuchbinderS, KratzschJ, FiedlerGMet al.Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest, 2008; 68,2:140–144.
29.
CauciS, Di SantoloM, CulhaneJF, StelG, GonanoF, GuaschinoS. Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol, 2008; 111,4:857–864.
30.
DolanSE, HadiganC, KillileaKMet al.Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr., 2005; 39,1:44–54.
31.
MasiaM, BernalE, PadillaSet al.The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis, 2007; 195,1:167–171.
32.
BogerMS, ShintaniA, RedhageLAet al.Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: A longitudinal study. J Acquir Immune Defic Syndr, 2009; 52,4:480–487.
